Overview
Study information
| Network: | CAVD |
| Grant Affiliation: | Schief (INV-005175): Experimental Medicine FIH of mRNA-HIV Immunogens |
| Strategy: | mRNA vaccines |
| Study Type: | Phase I |
| Species: | Human |
| Stage: | In progress |
| Study Start Date: | NA |
| Study Made Public: | NA |
Title
A Phase 1, randomized, first-in-human, open-label study to evaluate the safety and immunogenicity of eOD-GT8 60mer mRNA vaccine (mRNA-1644) and Core-g28v2 60mer mRNA vaccine (mRNA-1644v2-Core) in HIV-1 uninfected adults in good general health
Description
CAVD 856 (IAVI G002) is a Phase 1, clinical trial to evaluate the safety and immunogenicity of eOD-GT8 60mer mRNA and Core-g28v2 60mer mRNA vaccines.
Sign in to see full information about this study and to download study data.
Products
eOD-GT8 60mer mRNA Core-g28v2 60mer mRNAIntegrated data
No integrated data is available for this study.
Non-integrated data
No non-integrated data is available for this study.